Congress to subpoena AbbVie for providing ‘particularly poor’ drug pricing documents

In January 2019, the committee gathered data about rates plans for expensive medications from a dozen drugmakers to deal with the publics growing issues about prescription unaffordability. The subpoena is being provided since the committee believes AbbVie failed to offer adequate information regarding the prices of Humira, its rheumatoid arthritis treatment, and Imbruvica, a lymphoma drug.

Katie Adams –
Tuesday, September 1st, 2020
Print|Email.

” The volume and quality of AbbVies actions are inconsistent with the expected recordkeeping and decision-making procedures of a big multi-national corporation concerning 2 of its most successful drugs,” Ms. Maloney composed. “In addition, the volume and quality of AbbVies responses are especially poor in contrast to the files produced by other companies that are the subject of the Committees investigation– particularly considered that the Committee is taking a look at two of AbbVies most successful items.”.

” Weve been working cooperatively with the House Oversight Committee considering that we received their initial letter in January 2019,” an AbbVie representative told STAT. “In fact, weve offered thousands of documents and have actually had many discussions with the Committee staff. While we are dissatisfied and shocked the Committee chose to take this action, we will continue to work in great faith with them on this essential topic.”.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.

In 2019, Humira brought AbbVie $14.8 billion in sales in the U.S. alone, according to STAT. The drugmaker has actually acquired dozens of patents to protect the drug against competition from generic drugmakers, a method it likewise utilizes to safeguard Imbruvica sales..

Bayer to get vitamin subscription company for $225M.

Your House Committee on Oversight and Reform is preparing to subpoena AbbVie for paperwork relating to two of its most profitable drugs, according to a memo composed by Rep. Carolyn Maloney, D-N.Y.

” Weve been working cooperatively with your home Oversight Committee given that we got their preliminary letter in January 2019,” an AbbVie representative told STAT. “In truth, weve provided thousands of files and have actually had numerous discussions with the Committee staff. While we are dissatisfied and surprised the Committee picked to take this action, we will continue to operate in excellent faith with them on this crucial topic.”.

More posts on pharmacy: Mylan remembers 2 drugs after label mix-upNovartis develops new sustainability goalsBayer to acquire vitamin membership business for $225M.

AbbVie has at least 88 patents for Imbruvica, which guarantees the company unique rights to sell the drug up until at least 2036. Its list rate is $174,000.